Congratulations to Professor David Seiffge from Stroke Research Center Bern for receiving the #stroke award by DGN and DSG at #DGN23! Your dedication, passion, and groundbreaking contributions to stroke patients are truly inspiring and deserving of this prestigious recognition. 🏆👏

Die komplett überarbeiteten und aktualisierten #Stroke #Guidelines 2024 von Stroke Research Center Bern Insel Gruppe sind zum kostenlosen Download verfügbar! Dank Simon Jung, Thomas Meinel & Team ein unerlässlicher Wissensschatz und Wegleitung für junge Kolleg:innen. neurologie.insel.ch/fileadmin/Neur…

Time for “code ICH”? – Workflow metrics of hyperacute treatments and outcome in patients with intracerebral haemorrhage karger.com/ced/article/do…

🍾Congratulations to our «Young Talents in Clinical Research» Grantees 2023: Luisa von den Driesch, Cédric Kissling, Julia Bardoczi, and Bernhard M. Siepen Bernhard Siepen (clockwise from top left)!👏 Learn about their projects: medizin.unibe.ch/research/index… Universität Bern Insel Gruppe Child and Adolescent Psychiatry Bern

Bernhard Siepen from Stroke Research Center Bern on hemostatic therapy for #hemorrhagic #stroke 🩸🧠 Promising data from TICH-NOAC and ANNEXA4 on efficacy of Andexanet as compared to PCC. Stay tuned for the publication ... 👏💪 David Seiffge

Spectrum of OAC-ICH changed dramatically, FXaI now the majority. Poor outcomes with current reversal, need better treatments. Great Norwegian-Swiss collaboration Stroke Research Center Bern Bernhard Siepen Espen Saxhaug Kristoffersen Johannes Kaesmacher Thomas Meinel Urs Martin Fischer Martina Göldlin svn.bmj.com/content/early/…

Now Online! 🗞️#Andexanet alfa versus non-specific treatments for #intracerebral #hemorrhage in patients taking factor Xa inhibitors — Individual patient data analysis of ANNEXA-4 and TICH-NOAC. journals.sagepub.com/doi/abs/10.117… David Seiffge Bernhard Siepen Stroke Research Center Bern

New non-randomized comparidon of andexanet alfa and usual care (i.e. PCC and/or TXA) in patients with factorXa-inhibitor- ICH - high rate of continuous bleeding (aka haematoma expansion) with usual care. Andexanet was associated with lower incidence of HE Stroke Research Center Bern Bernhard Siepen

Bernhard Siepen from Stroke Research Center Bern presenting the MAX-ICH trial (supported by Schweizerische Herzstiftung ) at the European Stroke Org ICH academy at #ESOC2024 in Basel - the next step for ICH treatment?

In our latest study published today in European Stroke Org , we analyzed the safety of those more liberal decisions. A team effort by Philipp Bücke Simon Jung Johannes Kaesmacher David Seiffge Martina Göldlin Morin Beyeler, MD Urs Martin Fischer Thomas Meinel journals.sagepub.com/doi/10.1177/23…

Excellent start to #ESOC with lively discussions after extraordinary talks at the #ESO ICH Academy, thanks to the organizers! It was a pleasure chairing…. Laurent Puy, Andrea Morotti,and European Stroke Org

Had a honor to moderate the session of the #stroke #services together with Manuel Requena from Spain - we had impressive speakers from 🇩🇪 , 🇦🇺 ,🇨🇭 Mobile stroke units and even flying teams: all leads to an improvement of the mRS European Stroke Org #ESOC2024

The ANNEXa-I primary results manuscript is now available NEJM. nejm.org/doi/full/10.10… #stroke #neurotwitter @McMasterStroke McMaster University Department of Medicine PHRI.ca Population Health Research Institute 🇨🇦 David Seiffge Else C. Sandset Mike Sharma Andrew Demchuk Carlos Molina Professor Hanne Christensen @robinlemmens

So honoured our planned MAX-ICH pilot study 🧠🩸 received the IAM award 2024 for best research project. Thanks to European Stroke Org and organisers Laurent Puy, Andrea Morotti & Thorsten Steiner. Would not be possible without @davidseiffge @researchbern 🙏🏻

Congratulations to David Seiffge & Urs Martin Fischer representing European Stroke Org in the board of directors and as the incoming president. We can't wait to see the impact you'll make. Proud to have you on our team!

Do all patients with ICH need treatement at a hospital with neurosurgery? Probably not: this large prospectice study from Catalunya showed no difference in outcome according to hospital type neurology.org/doi/10.1212/WN… Treatment of ICH is as easy as ABC neurology.org/doi/10.1212/WN…

#FlashbackFriday ! 🗞️#Andexanet alfa versus non-specific treatments for #intracerebral #hemorrhage in patients taking factor Xa inhibitors — Individual patient data analysis of ANNEXA-4 and TICH-NOAC. journals.sagepub.com/doi/abs/10.117… David Seiffge Bernhard Siepen Stroke Research Center Bern

Latest updates in the gudielines of ICH management 🧠🩸by Bernhard Siepen at Bern Stroke & Brain Health Symposium. Andexanet alfa in DOAC-associated ICH showed lower rates of HE - but this did not translate into better functional outcome ❌️

That’s a great programme connecting stroke enthusiasts! We were lucky to welcome many brillant young doctors at Stroke Research Center Bern Insel Gruppe over the last years - please get in touch if you are interested Urs Martin Fischer Thomas Meinel European Stroke Master Martina Göldlin Bernhard Siepen Espen Saxhaug Kristoffersen

Globally, intracerebral haemorrhage causes more loss of healthy life years than ischaemic stroke. We must prioritise ICH to reduce its burden through public health interventions, research, and improved healthcare. See our open access World Stroke Org factsheet 👇🏻